JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.

Hypereosinophilic syndromes may result either from eosinophilic differentiation of a clone of neoplastic cells or from reactive eosinophilia. In other patients HES is idiopathic. It appears likely that in many patients the "idiopathic' hypereosinophilic syndrome is actually a chronic myeloproliferative disorder. Those cases showing an increase of blast cells or a demonstrable clonal cytogenetic abnormality should be classified as eosinophilic leukaemia. In other cases the neoplastic nature of the disease can be recognized only in retrospect when a granulocytic sarcoma or AMI, develops. A few cases of idiopathic HES are consequent on cytokine secretion whereas others remain idiopathic at the time of death. When eosinophilia occurs as a feature of an acute or chronic myeloid leukaemia or a chronic myeloproliferative disorder the eosinophils are usually part of the leukaemic clone. However, eosinophilia in association with acute lymphoblastic leukaemia is usually reactive. Rare cases have a biphenotypic leukaemia/lymphoma with both eosinophils and lymphoid cells arising from a mutant pluripotent stem cell.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app